Table 4 Treatment efficacy in acquired angioedema C1-inhibitor patients with anti-C1-INH autoantibodies (N = 8)
Patient | Gender (M/F) | Type of anti-C1-INH autoantibodies | Untreated attacks (n) | Mean duration of untreated attacks (h) | Treated attacks (n) | Mean duration of treated attacks a (h) | Mean shortening of attacks with treatment (h, (%)) | Effectively treated attacks b (n (%)) |
|---|---|---|---|---|---|---|---|---|
1 | F | IgG | 124 | 72 | 820 | 9.5 | 62.5 (86.8) | 820 (100) |
2 | M | IgG, IgM | 208 | 60 | 13 | 79 | −19 (−31.7) | 1 (8.3) |
3 | M | IgG | 648 | 84 | 12 | 41.5 | 42.5 (50.6) | 12 (100) |
4 | M | IgG, IgM | 79 | 96 | 16 | 26 | 70 (72.9) | 16 (100) |
5 | F | IgA | 89 | 84 | 24 | 38 | 46 (54.8) | 22 (91.7) |
6 | M | IgG | 59 | 96 | 303 | 24.25 | 71.75 (74.7) | 303 (100) |
7 | M | IgG, IgM | 144 | 120 | 71 | 11 | 109 (90.8) | 70 (98.6) |
8 | F | IgG, IgM | 283 | 72 | 70 | 51.5 | 20.5 (28.5) | 68 (97.1) |
Total | – | – | 1634 | – | 1329 | – | – | 1246 (93.8) |